Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs

BACKGROUND: Ovarian and triple-negative breast cancers with BRCA1 or BRCA2 loss are highly sensitive to treatment with PARP inhibitors and platinum-based cytotoxic agents and show an accumulation of genomic scars in the form of gross DNA copy number aberrations. Cancers without BRCA1 or BRCA2 loss b...

Descripción completa

Detalles Bibliográficos
Autores principales: Marquard, Andrea M, Eklund, Aron C, Joshi, Tejal, Krzystanek, Marcin, Favero, Francesco, Wang, Zhigang C, Richardson, Andrea L, Silver, Daniel P, Szallasi, Zoltan, Birkbak, Nicolai J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443545/
https://www.ncbi.nlm.nih.gov/pubmed/26015868
http://dx.doi.org/10.1186/s40364-015-0033-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443545/
https://www.ncbi.nlm.nih.gov/pubmed/26015868
http://dx.doi.org/10.1186/s40364-015-0033-4

Ejemplares similares